+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID07235085

Phase 3 Study of OTX-TKI Axitinib Implant Delivered by Eye Injection to Treat Non-Proliferative Diabetic Retinopathy

Led by Ocular Therapeutix, Inc. · Updated on 2026-03-16

930

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of OTX-TKI, an axitinib intravitreal hydrogel implant, for treating Non-Proliferative Diabetic Retinopathy NPDR. This phase 3 trial compares OTX-TKI with a sham injection procedure to better understand its impact on this eye condition. OTX-TKI slowly releases the drug axitinib inside the eye to potentially improve disease outcomes. Participants receive either a single OTX-TKI injection followed by a sham procedure at week 24, two OTX-TKI injections at day 1 and week 24, or two sham procedures at day 1 and week 24. Only one eye, called the study eye, will be treated, and the sham injection is a mock procedure without a needle. During the study, participants will have their eye condition monitored, including changes in the Diabetic Retinopathy Severity Scale DRSS at week 52. Visual acuity and safety will be assessed through scheduled clinic visits and eye imaging. The study lasts for at least 52 weeks, with careful monitoring for treatment effects and adverse events throughout this period.

CONDITIONS

Brief Title

A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy

Research Team

C

Clinical Project Manager

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here